The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
DT-diaphorase is a unique two electron (2e) donating reductase catalyzing either bioactivation or bioprotection reactions. Using human and rodent DT-diaphorase preparations (cell extracts and purified enzyme) we have characterized the reductive metabolism of the hypoxic cell cytotoxins EO9, mitomycin C (MMC), CB 1954, and SR 4233 in vitro. Drug metabolism was assayed spectrophotometrically or by HPLC, with dicoumarol as a selective inhibitor. DNA damage was measured using an agarose gel mobility technique with plasmid pBR322 DNA. The developmental indoloquinone, EO9, was metabolized by both rat Walker and human HT29 tumor DT-diaphorases. Reduction proceeded 5-fold more efficiently with the rat than the human tumor enzyme and resulted in single-strand breaks in plasmid DNA. The structurally related MMC was metabolized much more slowly than EO9 by the rat Walker tumor enzyme and there was no detectable reaction with the human HT29 tumor DT-diaphorase. No DNA damage was seen with MMC for either enzyme. The dinitrophenylaziridine CB 1954 was reduced by both human and rat enzymes forming, preferentially, the highly toxic 4-hydroxylamine as a 4e reduction product. Rates were 3-fold lower than for the human tumor enzyme. SR 4233 was also reduced by the rat tumor enzyme predominantly via 4e reduction to the benzotriazine SR 4330, in a novel reaction mechanism. This appears to be a bioprotection pathway that bypasses the toxic 1e radical formed by other reductases. Such information may be valuable in the selection of hypoxic cell cytoxins to treat human tumors high or low in DT-diaphorase and should facilitate 'enzyme-directed' analogue development.
Walton
M I
MI
MRC Clinical Oncology and Radiotherapeutics Unit, Cambridge, UK.
Sugget
N
N
Workman
P
P
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D001388:Aziridines / Q000378:metabolism; D002279:Carcinoma 256, Walker / Q000201:enzymology; D015687:Cell Hypoxia / Q000187:drug effects; D003110:Colonic Neoplasms / Q000201:enzymology; D006801:Humans; D066298:In Vitro Techniques; D045563:Indolequinones; D007211:Indoles / Q000378:metabolism; D016685:Mitomycin / Q000378:metabolism; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000502:physiology*; D010084:Oxidation-Reduction; D011355:Prodrugs / Q000378:metabolism*; D051381:Rats; D000077704:Tirapazamine; D014227:Triazines / Q000378:metabolism
D000970:Antineoplastic Agents; D001388:Aziridines; D045563:Indolequinones; D007211:Indoles; D011355:Prodrugs; D014227:Triazines; D000077704:Tirapazamine; D016685:Mitomycin; C100099:tretazicar; D016660:NAD(P)H Dehydrogenase (Quinone); C060817:apaziquone